179 related articles for article (PubMed ID: 34651515)
1. Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice.
Bilcke J; Beutels P
Med Decis Making; 2022 May; 42(4):421-435. PubMed ID: 34651515
[TBL] [Abstract][Full Text] [Related]
2. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
3. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
4. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
5. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
7. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
8. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
10. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
11. A new approach for sample size calculation in cost-effectiveness studies based on value of information.
Bader C; Cossin S; Maillard A; Bénard A
BMC Med Res Methodol; 2018 Oct; 18(1):113. PubMed ID: 30348087
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
13. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
Karnon J; Czoski-Murray C; Smith K; Brand C; Chakravarthy U; Davis S; Bansback N; Beverley C; Bird A; Harding S; Chisholm I; Yang YC
Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
[TBL] [Abstract][Full Text] [Related]
14. Value-of-Information Analysis for External Validation of Risk Prediction Models.
Sadatsafavi M; Lee TY; Wynants L; Vickers AJ; Gustafson P
Med Decis Making; 2023 Jul; 43(5):564-575. PubMed ID: 37345680
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and value of information analysis of a low-friction environment following skin graft in patients with burn injury.
Kandiyali R; Thom H; Young AE; Greenwood R; Welton NJ
Pilot Feasibility Stud; 2020; 6():8. PubMed ID: 32021697
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.
Chen YF; Madan J; Welton N; Yahaya I; Aveyard P; Bauld L; Wang D; Fry-Smith A; Munafò MR
Health Technol Assess; 2012; 16(38):1-205, iii-v. PubMed ID: 23046909
[TBL] [Abstract][Full Text] [Related]
17. Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses.
Müller D; Pullenayegum E; Gandjour A
Eur J Health Econ; 2015 Mar; 16(2):219-23. PubMed ID: 24840608
[TBL] [Abstract][Full Text] [Related]
18. [Probabilistic cost-effectiveness analysis of the treatment of sleep apnea].
Mar J; Gutiérrez-Moreno S; Chilcott J
Gac Sanit; 2006; 20(1):47-53. PubMed ID: 16539993
[TBL] [Abstract][Full Text] [Related]
19. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of ovarian stimulation agents for IUI in couples with unexplained subfertility.
van Eekelen R; Wang R; Danhof NA; Mol F; Mochtar M; Mol BW; van Wely M
Hum Reprod; 2021 Apr; 36(5):1288-1295. PubMed ID: 33615360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
